DK1393744T3 - Acellulære pertussisvacciner og fremgangsmåder til fremstilling heraf - Google Patents

Acellulære pertussisvacciner og fremgangsmåder til fremstilling heraf

Info

Publication number
DK1393744T3
DK1393744T3 DK03078355.9T DK03078355T DK1393744T3 DK 1393744 T3 DK1393744 T3 DK 1393744T3 DK 03078355 T DK03078355 T DK 03078355T DK 1393744 T3 DK1393744 T3 DK 1393744T3
Authority
DK
Denmark
Prior art keywords
pref
iii
pertussis
toxoid
agg
Prior art date
Application number
DK03078355.9T
Other languages
English (en)
Inventor
John R Vose
Gail E D Jackson
Larry U L Tan
Andrew Herbert
Leslie Boux
Luis Barreto
John Thipphawong
Michael H Klein
Raafat E Fahim
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/433,646 external-priority patent/US5877298A/en
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of DK1393744T3 publication Critical patent/DK1393744T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK03078355.9T 1995-05-04 1996-05-02 Acellulære pertussisvacciner og fremgangsmåder til fremstilling heraf DK1393744T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/433,646 US5877298A (en) 1995-05-04 1995-05-04 Acellular pertussis vaccines and methods of preparing thereof
US50174395A 1995-07-12 1995-07-12
EP02012063A EP1234579A1 (en) 1995-05-04 1996-05-02 Acellular Pertussis Vaccines and Methods of Preparation Thereof

Publications (1)

Publication Number Publication Date
DK1393744T3 true DK1393744T3 (da) 2011-05-30

Family

ID=27029924

Family Applications (3)

Application Number Title Priority Date Filing Date
DK96911887T DK0826001T3 (da) 1995-05-04 1996-05-02 Acellulære pertussisvacciner og fremgangsmåder til fremstilling heraf
DK96911886T DK0824358T3 (da) 1995-05-04 1996-05-02 Acellulære pertussisvacciner og fremgangsmåder til fremstilling deraf
DK03078355.9T DK1393744T3 (da) 1995-05-04 1996-05-02 Acellulære pertussisvacciner og fremgangsmåder til fremstilling heraf

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK96911887T DK0826001T3 (da) 1995-05-04 1996-05-02 Acellulære pertussisvacciner og fremgangsmåder til fremstilling heraf
DK96911886T DK0824358T3 (da) 1995-05-04 1996-05-02 Acellulære pertussisvacciner og fremgangsmåder til fremstilling deraf

Country Status (17)

Country Link
US (1) US6399076B2 (da)
EP (7) EP0826001B1 (da)
CN (2) CN1198099A (da)
AT (3) ATE221081T1 (da)
AU (2) AU710538B2 (da)
BR (2) BR9608114A (da)
CA (3) CA2433502A1 (da)
DE (3) DE69638326D1 (da)
DK (3) DK0826001T3 (da)
ES (2) ES2180758T3 (da)
FR (1) FR16C0015I2 (da)
LU (1) LU93036I2 (da)
MX (1) MX9708481A (da)
NL (1) NL300804I2 (da)
NZ (2) NZ306391A (da)
PT (3) PT1393744E (da)
WO (2) WO1996034883A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) * 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
US6051240A (en) * 1994-04-28 2000-04-18 Takeda Chemical Industries, Ltd. Method of separating protective components of Bordetella pertussis
US6696065B1 (en) * 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
BRPI9710460B8 (pt) * 1996-07-02 2021-05-25 Aventis Pasteur composição imunogênica multi-valente e composição de vacina
EP1123711B9 (en) * 1998-10-21 2009-08-12 The Kitasato Institute Attenuated toxins as adjuvants
CN1906307B (zh) * 2003-11-20 2011-08-24 圣诺菲·帕斯图尔公司 纯化百日咳毒素的方法及其中有用的肽
CN101203605B (zh) * 2004-12-17 2016-01-27 由卫生福利和体育大臣代表的荷兰王国 革兰氏阴性菌的lps的脱酰基化
CA2618306C (en) 2005-08-08 2014-10-21 Oregon Health & Science University Inactivating pathogens with hydrogen peroxide for vaccine production
EP1867638A1 (de) * 2006-06-16 2007-12-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur kovalenten Verknüpfung zweier Moleküle mittels Diels-Alder-Reaktion mit inversem Elektronenbedarf
US8945582B2 (en) 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
CN100537767C (zh) * 2007-04-29 2009-09-09 中国药品生物制品检定所 百日咳疫苗保护性抗原的重组表达及其应用
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
US20100330158A1 (en) * 2009-03-31 2010-12-30 Innopharma, Llc Protein-assisted drug delivery system for the targeted administration of active agents
EP2430040A1 (en) 2009-05-11 2012-03-21 Novartis AG Antigen purification process for pertactin antigen
CN103814048A (zh) * 2011-09-20 2014-05-21 生物辐射实验室股份有限公司 从生物分子制剂中去除杀病毒剂
WO2013049535A2 (en) 2011-09-30 2013-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Influenza vaccine
CN102584958A (zh) * 2012-02-08 2012-07-18 北京天坛生物制品股份有限公司 百日咳杆菌69kd外膜蛋白的纯化方法
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
AP2015008702A0 (en) 2013-03-08 2015-09-30 Crucell Holland Bv Acellular pertussis vaccine
CN107921407B (zh) 2015-06-05 2022-07-05 格雷斯公司 生物处理吸附澄清剂及其制备和使用方法
CN105106947A (zh) * 2015-07-21 2015-12-02 华兰生物工程股份有限公司 过氧化氢脱毒的无细胞百日咳疫苗及其制备方法
US11602559B2 (en) 2016-10-03 2023-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV-1 Env fusion peptide immunogens and their use
WO2018081832A1 (en) 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
EP3600405B1 (en) 2017-03-24 2025-08-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Glycan-masked engineered outer domains of hiv-1 gp120 and their use
KR102426041B1 (ko) * 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
EP3697440A1 (en) 2017-10-16 2020-08-26 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
US12053519B2 (en) 2018-09-23 2024-08-06 The United States Of America, As Represented By The Secretary Department Of Health And Human Services HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
EP3870703A1 (en) 2018-10-22 2021-09-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant gp120 protein with v1-loop deletion
CN110358802B (zh) * 2019-08-16 2021-06-18 长春百克生物科技股份公司 一种去除百日咳组分菌毛蛋白2/3内毒素的方法
US12210017B2 (en) 2020-01-08 2025-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptides representing epitopes from filoviruses
CN112094354B (zh) * 2020-11-05 2021-02-02 苏州世诺生物技术有限公司 副鸡禽杆菌基因工程亚单位疫苗、其制备方法及应用
AU2022323509A1 (en) 2021-08-03 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
US20250197455A1 (en) 2022-03-27 2025-06-19 TThe United States of America, as represented by the Secretary, Department of Health and Human Servi Base-covered hiv-1 envelope ectodomains and their use
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗
WO2024249626A1 (en) 2023-05-30 2024-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 envelope triple tandem trimers and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
US4705686A (en) 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
KR0168039B1 (ko) * 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
US4967176A (en) * 1988-07-15 1990-10-30 Raychem Corporation Assemblies of PTC circuit protection devices
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
IL93957A0 (en) * 1989-03-31 1990-12-23 Univ Washington Bordetella outer membrane proteins,their use in vaccines and their expression
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
US6051240A (en) * 1994-04-28 2000-04-18 Takeda Chemical Industries, Ltd. Method of separating protective components of Bordetella pertussis
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof

Also Published As

Publication number Publication date
HK1016191A1 (zh) 1999-10-29
FR16C0015I1 (da) 2016-06-10
DE69622555T2 (de) 2003-03-27
EP1393744A1 (en) 2004-03-03
LU93036I2 (fr) 2016-06-21
DE69638326D1 (de) 2011-03-10
DK0826001T3 (da) 2002-11-18
AU5494096A (en) 1996-11-21
DE69625191D1 (de) 2003-01-16
MX9708481A (es) 1998-02-28
BR9608114A (pt) 2000-10-31
CA2220063C (en) 2003-08-26
AU715417B2 (en) 2000-02-03
PT1393744E (pt) 2011-05-03
NZ306391A (en) 1999-03-29
ATE496634T1 (de) 2011-02-15
ES2182971T3 (es) 2003-03-16
EP1233022B1 (en) 2015-12-09
CA2433502A1 (en) 1996-11-07
WO1996034623A1 (en) 1996-11-07
DE69622555D1 (de) 2002-08-29
EP0826001A1 (en) 1998-03-04
FR16C0015I2 (fr) 2017-06-09
EP1234580A1 (en) 2002-08-28
US20010009666A1 (en) 2001-07-26
CA2220063A1 (en) 1996-11-07
WO1996034883A1 (en) 1996-11-07
PT826001E (pt) 2002-12-31
EP0824358B1 (en) 2002-12-04
PT824358E (pt) 2003-02-28
ES2180758T3 (es) 2003-02-16
CA2220048A1 (en) 1996-11-07
DE69625191T2 (de) 2003-07-10
CA2220048C (en) 2006-03-07
CN1198099A (zh) 1998-11-04
EP1234579A1 (en) 2002-08-28
CN100387618C (zh) 2008-05-14
ATE221081T1 (de) 2002-08-15
NZ306392A (en) 1999-04-29
AU710538B2 (en) 1999-09-23
US6399076B2 (en) 2002-06-04
DK0824358T3 (da) 2003-01-27
EP0826001B1 (en) 2002-07-24
EP0824358A1 (en) 1998-02-25
CN1193324A (zh) 1998-09-16
EP1393744B1 (en) 2011-01-26
NL300804I2 (da) 2016-11-01
EP1405643A1 (en) 2004-04-07
ATE228851T1 (de) 2002-12-15
AU5494196A (en) 1996-11-21
EP1233022A1 (en) 2002-08-21
BR9608115A (pt) 2004-07-13

Similar Documents

Publication Publication Date Title
DK0824358T3 (da) Acellulære pertussisvacciner og fremgangsmåder til fremstilling deraf
AU4267093A (en) Vaccine compositions for mucosal delivery
RU99101850A (ru) Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно(акдс)-полиомиелитные вакцины
CA2271008A1 (en) Acellular pertussis vaccine with diphtheria- and tetanus-toxoids
LU91591I2 (fr) Combinaison d'antoxine diphtérique, d'anatoxine tétanique,d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine, d'agglutinogènes fimbriaux coquelucheux 2 et 3 et de virus poliomyélitique inactivé type1, type 2 et type 3 (Triaxis Polio)
EP0761230A3 (en) Vaccine containing Bordetella pertussis outer membrane protein, and method of making such vaccine
EP0722338A4 (en) Vaccines consisting of protein or peptide "cochlates" and their use for immunization
CA2427475A1 (en) Purification of hbv antigens for use in vaccines
CA2386023A1 (en) Mucosal dtpa vaccines
WO1997046255A3 (en) Vaccine composition comprising outer membrane protein fragments of bordetella pertussis
MXPA99004278A (es) Vacuna de pertusis acelular con toxoides de difteria y tetanos